Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 08 2019
Historique:
received: 24 05 2019
revised: 28 06 2019
accepted: 02 07 2019
pubmed: 16 7 2019
medline: 21 10 2020
entrez: 15 7 2019
Statut: ppublish

Résumé

The death receptor CD95 (also known as Fas) induces apoptosis through protein/protein association and the formation of the death-inducing signaling complex. On the other hand, in certain biological conditions, this receptor recruits different proteins and triggers the formation of another complex designated motility-inducing signaling complex, which promotes cell migration and inflammation. This pathway relies on a short sequence of CD95, called calcium-inducing domain (CID), which interacts with the phospholipase PLCγ1. To better understand how CID/PLCγ1 interaction occurs, we synthesized different α-AA peptides mimicking CID. Some of these peptidomimetics are as potent as the natural peptide to disrupt the CID/PLCγ1 interaction and cell migration, and showed improved pharmacokinetic properties. We also generated biotinyl- and palmitoyl-labelled peptidomimetics, useful chemico-biological tools to further explore the pro-inflammatory signal of CD95, which plays an important role in the pathogenesis of lupus and other autoimmune diseases.

Identifiants

pubmed: 31301931
pii: S0960-894X(19)30451-2
doi: 10.1016/j.bmcl.2019.07.006
pii:
doi:

Substances chimiques

FAS protein, human 0
Peptidomimetics 0
fas Receptor 0
Biotin 6SO6U10H04
PLCG1 protein, human EC 3.1.4.11
Phospholipase C gamma EC 3.1.4.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2094-2099

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Ha Thanh Nguyen (HT)

CLCC Eugène Marquis, INSERM, Univ Rennes 1, UMR1242, rue Bataille Flandres Dunkerque, 35042 Rennes, France; Equipe Ligue Contre Le Cancer, rue Bataille Flandres Dunkerque, 35042 Rennes, France.

Jean-Philippe Guégan (JP)

CLCC Eugène Marquis, INSERM, Univ Rennes 1, UMR1242, rue Bataille Flandres Dunkerque, 35042 Rennes, France; Equipe Ligue Contre Le Cancer, rue Bataille Flandres Dunkerque, 35042 Rennes, France.

Amanda Poissonnier (A)

CLCC Eugène Marquis, INSERM, Univ Rennes 1, UMR1242, rue Bataille Flandres Dunkerque, 35042 Rennes, France; Equipe Ligue Contre Le Cancer, rue Bataille Flandres Dunkerque, 35042 Rennes, France.

Florence Jouan (F)

CLCC Eugène Marquis, INSERM, Univ Rennes 1, UMR1242, rue Bataille Flandres Dunkerque, 35042 Rennes, France; Equipe Ligue Contre Le Cancer, rue Bataille Flandres Dunkerque, 35042 Rennes, France.

Daniel Best (D)

CLCC Eugène Marquis, INSERM, Univ Rennes 1, UMR1242, rue Bataille Flandres Dunkerque, 35042 Rennes, France; Equipe Ligue Contre Le Cancer, rue Bataille Flandres Dunkerque, 35042 Rennes, France.

Pierre van de Weghe (P)

CLCC Eugène Marquis, INSERM, Univ Rennes 1, UMR1242, rue Bataille Flandres Dunkerque, 35042 Rennes, France; Equipe Ligue Contre Le Cancer, rue Bataille Flandres Dunkerque, 35042 Rennes, France.

Pierre Vacher (P)

Université de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France; INSERM U1218, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France.

Nicolas Levoin (N)

Bioprojet Biotech, 4 rue du Chesnay Beauregard, 35760 Saint-Grégoire, France. Electronic address: n.levoin@bioprojet.com.

Patrick Legembre (P)

CLCC Eugène Marquis, INSERM, Univ Rennes 1, UMR1242, rue Bataille Flandres Dunkerque, 35042 Rennes, France; Equipe Ligue Contre Le Cancer, rue Bataille Flandres Dunkerque, 35042 Rennes, France. Electronic address: plegembre@hotmail.com.

Mickael Jean (M)

CLCC Eugène Marquis, INSERM, Univ Rennes 1, UMR1242, rue Bataille Flandres Dunkerque, 35042 Rennes, France; Equipe Ligue Contre Le Cancer, rue Bataille Flandres Dunkerque, 35042 Rennes, France. Electronic address: mickael.jean@univ-rennes1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH